Ad-hoc: Marinomed Biotech AG begins contract negotiations for the sale of the Carragelose portfolio
Marinomed Biotech AG publishes remarkable results showing alleviation of allergic eye inflammation in patients treated with Tacrolimus eye drops in peer-reviewed journal
Marinomed Biotech AG reports positive clinical results for unique Carragelose eye drops
Ad-hoc: Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 154,053 no-par value bearer shares at an issue price of EUR 5 per share
Lucia Ziegler, MSc
Head of Investor & Public Relations